Published by Frank Prenesti on 14th July 2025
(Sharecast News) - GSK said the US Food and Drug Administration has accepted an application for review to extend the indication of its Arexvy respiratory syncytial virus vaccine to adults aged 18-49 who are at increased risk.
URL: http://www.digitallook.com/dl/news/story/35213622/...